Coherus BioSciences, Inc., a biosimilar company, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Humira biosimilar, Yusimry (adalimumab-aqvh). Yusimry is expected to be available in the U.S. on or after July 1, 2023.
Humira is the world's top-selling biologic drug, with annual sales of over $16 billion. Yusimry is the first biosimilar to Humira to be approved by the FDA. Biosimilars are similar to biologic drugs, but they are not identical. Biosimilars are designed to be as safe and effective as the biologic drugs they are based on.
The approval of Yusimry is expected to increase competition in the market for Humira. This could lead to lower prices for patients who need Humira or a biosimilar.
Coherus BioSciences is a commercial-stage biosimilar company focused on developing and commercializing biosimilars to complex protein products. The company's product portfolio includes biosimilars to Humira, Avastin, and Lucentis.
About Coherus BioSciences
Coherus BioSciences, Inc. is a commercial-stage biosimilar company focused on developing and commercializing biosimilars to complex protein products. The company's product portfolio includes biosimilars to Humira, Avastin, and Lucentis. Coherus was founded in 2011 and is headquartered in Redwood City, California.
About Humira
Humira is a biologic drug that is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Humira is the world's top-selling biologic drug, with annual sales of over $16 billion.
About Biosimilars
Biosimilars are similar to biologic drugs, but they are not identical. Biosimilars are designed to be as safe and effective as the biologic drugs they are based on. Biosimilars are regulated by the FDA as biologic drugs.
The Impact of Yusimry's Approval
The approval of Yusimry is expected to increase competition in the market for Humira. This could lead to lower prices for patients who need Humira or a biosimilar. Yusimry is the first biosimilar to Humira to be approved by the FDA. Biosimilars are similar to biologic drugs, but they are not identical. Biosimilars are designed to be as safe and effective as the biologic drugs they are based on.
People also ask
⚐ What are the top stocks to invest in right now?☵ What happens to stocks when they're delisted?